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ABSTRACT55
56
Background. Proteolytic cleavage of the amyloid precursor protein (APP) by secretases leads57
to extracellular release of amyloid β (Aβ) peptides. Increased production of Aβ42 over Aβ40 58
and aggregation into oligomers and plaques constitute an Alzheimer’s disease (AD) hallmark.59
Objectives. Identifying products of the ‘human chemical exposome’ (HCE) able to induce60
Aβ42 production is key to understand the initiating causes of AD and to generate non-genetic 61
animal models of AD.62
Methods. A cell model was used to screen chemical libraries for Aβ42 inducers. Active 63
molecules were extensively characterized.64
Results. Six herbicides triazines induced a 2-10 fold increase in the production of65
extracellular Aβ42 in various cell lines, primary neuronal cells and neurons differentiated 66
from human induced pluripotent stem cells (iPSCs). Induced Aβ42 production by triazines 67
requires active secretases. Immunoprecipitation/mass spectrometry analyses showed enhanced68
production of A peptides cleaved at positions 42 and 43, and reduced production of peptides69
cleaved at positions 38 and lower. Neurons derived from iPSCs obtained from a familial AD70
(FAD) patient (APP K724N) produced more Aβ42 vs. Aβ40 than neurons derived from71
healthy controls iPSCs (APP WT). Triazines further enhanced Aβ42 production in both 72
control and AD neurons. Triazines also shifted the cleavage pattern of alcadeins, another73
family of γ-secretase substrates, suggesting a direct effect of triazines on γ-secretase.74
Conclusions. Some widely used triazines enhance the production of toxic, aggregation-prone75
Aβ42/Aβ43 amyloids, suggesting the possible existence of environmental ‘Alzheimerogens’ 76
which may contribute to the initiation and propagation of the amyloidogenic process in AD.77
78
79
80
INTRODUCTION81
82
Proteolytic processing of amyloid precursor protein (APP) by β- and γ-secretases leads 83
to the production of various Aβ peptides, including the 42 amino acid form which plays a 84
crucial role in Alzheimer’s disease (AD) (Huang and Mucke 2012; Selkoe et al. 2012; Vinters85
2015). The action of β-secretase, or beta-site amyloid precursor protein cleaving enzyme 1 86
(BACE1), first leads to a soluble extracellular fragment (sAPPβ) and a membrane bound 87
fragment (βCTF, β-carboxyl-terminal fragment). γ-Secretase then acts on βCTF, leading to 88
the generation of Aβ peptides of various lengths and release of the APP intracellular domain 89
(AICD). Aβ peptides tend to aggregate as extracellular oligomers and ultimately as plaques, 90
one of the clinical hallmarks of AD.91
Aβ40 is the most abundantly produced Aβ peptide. Considerable data indicates that 92
generation of the aggregation-prone Aβ42 strongly correlates with the onset and development 93
of AD. In early onset AD (EOAD) (<1% of all cases), mutations in APP, or the γ-secretase 94
subunits PSEN1 & PSEN2 (review in Bateman et al. 2011), all lead to enhanced Aβ42 95
production and/or increased Aβ42/Aβ40 ratio, a critical factor in AD pathology initiation 96
(Kuperstein et al. 2010). Increased Aβ42/Aβ40 ratio is also found in brain tissue in late onset 97
AD (LOAD) (>99% of AD cases). Aβ42 is more toxic than Aβ40, a consequence of its higher 98
stability and strong tendency to oligomerize and to aggregate in plaques (McGowan et al.99
2005; Findeis 2007; Gouras et al. 2014). Aβ43 is also enriched in AD patients’ brains and has 100
been reported as a toxic, aggregation-prone amyloid, inducing strong AD phenotypes in mice101
(Welander et al. 2009; Saito et al. 2011; Sandebring et al. 2013; Conicella et al. 2014).102
We recently reported that some tri-substituted purines, the Aftins (Amyloid β Forty-103
Two Inducers), trigger a robust, secretases-dependent increase in extracellular Aβ42 104
production in cultured cells (Bettayeb et al. 2012; Hochard et al. 2013). Under these105
conditions Aβ38 levels dropped while Aβ40 remained relatively stable. These results suggest 106
that (i) such molecules might constitute new pharmacological tools to investigate the107
mechanisms underlying increased Aβ42/Aβ40 ratio observed in AD, (ii) these molecules108
might contribute to generate a chemically induced animal model of AD (Meunier et al. 2015)109
and (iii) some simple, low molecular weight (LMW) products in our environment might shift110
the Aβ42/Aβ40 ratio similarly to what is seen in AD patients and might thus contribute to the 111
development, acceleration or even initiation of LOAD.112
We therefore screened for potential Aβ42 inducing molecules in libraries of human 113
chemical exposome (HCE) products (Rappaport 2011; Wild 2005, 2012; Juarez et al. 2014;114
Vrijheid et al. 2014; Wishart et al. 2015). We here report that a subset of the widely used115
triazine herbicides is able to shift Aβ production towards longer, aggregation-prone amyloid 116
peptides (Aβ42/Aβ43) at the expense of shorter variants (Aβ37, Aβ38, Aβ40). In addition, 117
production of the shorter Aβ1-16 and Aβ1-17 peptides that are generated by sequential β- and 118
γ-secretase cleavages (Portelius et al. 2011; Pérez-Grijalba et al. 2015) was also enhanced. 119
This effect is observed in various cell lines, primary neuron cultures and neurons120
differentiated from iPSCs obtained from healthy or AD patients. Triazines shift the cleavage121
pattern of alcadeins, another family of γ-secretase substrates (Araki et al. 2007; Hata et al. 122
2009; Kamogawa et al. 2012; Piao et al. 2013; Omori et al. 2014), in a way similar to the APP123
cleavage shift, suggesting a direct effect on γ-secretase rather than on its substrates. 124
Altogether these data support our hypothesis that the HCE contains products able to modulate125
γ-secretase activity towards the production of high MW, aggregation prone, AD-associated 126
amyloids. Such products could be qualified as potential “Alzheimerogens”. Their127
identification and regulation might constitute a key step in AD prevention.128
129
130
METHODS131
132
Triazines and other reagents, cell lines and primary neuron cultures, cell viability,133
transient transfections with APP truncation mutants, human iPSCs-derived neuronal134
cultures, amyloids sample preparation and ELISA capture assays: see Supplementary135
Material.136
137
Mass spectrometric quantification of amyloids by selected reaction monitoring (SRM)138
Solid phase extraction, liquid chromatography and SRM analysis of Aβ species was 139
performed as described previously (Leinenbach et al. 2014; Pannee et al. 2013) with the140
following modifications. Standard curves for Aβ38 and 42 were prepared at 0.15, 0.5, 1, 2, 3 141
and 4 ng/mL while Aβ40 was prepared at 15, 50, 100, 200, 300 and 400 ng/mL using 142
unlabeled peptides (rPeptide) in DMEM/F12 supplemented with 0.5% FBS. Uniformly143
labeled 15N-Aβ38, 40 and 42 peptides (rPeptide) were added to a final concentration of 1.6 144
ng/mL in calibrators and unknown samples as internal standards. Standard curves were145
constructed using the unlabeled to 15N-Aβ peak area ratios and fitted using linear regression. 146
All standard curves were linear and had an R2 value greater than 0.998. Concentrations of147
unknowns were extrapolated from the standard curves using the peak area ratio of endogenous148
to 15N-Aβ. 149
150
Amyloids profile analysis by immunoprecipitation / mass spectrometry (IP-MS)151
Immunoaffinity capture of A species was combined with matrix-assisted laser152
desorption/ionization time-of-flight (MALDI-TOF) MS for analyzing a variety of A peptides153
in a single analysis as described (Portelius et al. 2007). In brief, the anti-Aβ antibodies 6E10 154
and 4G8 were separately coupled to magnetic beads. After washing of the beads, the 4G8 and155
6E10 coated beads were used in combination for immunoprecipitation. After elution of the156
immune-purified A peptides, analyte detection was performed on an UltraFlextreme MALDI157
TOF/TOF instrument (Bruker Daltonics). For each peak the areas were normalized against the158
sum for all the Aβ peaks in the spectrum followed by averaging of results for separately 159
determined duplicate samples (Brinkmalm et al. 2012; Portelius et al. 2013).160
161
HEK293 cell culture and Alcadein fragments analysis162
The full length human Alcadeinα1 (Alcα) open reading frame (Araki et al. 2003) was 163
subcloned into the HindIII and XbaI sites of pcDNA3.1 (Hygro+) vector (Invitrogen),164
transfected into HEK293 cells with Lipofectamine 2000, and cells stably expressing Alcα 165
were cloned. The cells cultured in dish coated with poly-L-lysine were treated with Aftin-5 or166
triazines (100 µM) for 24 h. The secreted p3-Alcα were recovered from the cultured medium 167
by immunoprecipitation with anti-p3-Alcα UT175 antibody, an antibody raised to a antigen 168
peptide composed of Cys plus the human Alcα1 839-851 sequence, using Protein G-169
Sepharose beads. The beads were sequentially washed and samples were eluted with170
trifluoroacetic acid/acetonitrile/water (1:20:20) saturated with sinapinic acid, and subject to171
MALDI-TOF/MS analysis using an Ultraflex II TOF/TOF (Bruker Daltonics). Molecular172
masses were calibrated using the peptide calibration standard (Bruker Daltonics) (Hata et al.173
2009).174
175
RESULTS176
177
Screening the HCE reveals triazines as Aβ42 inducers 178
A library of 3500+ LMW products representative of the HCE was assembled. All179
compounds were tested for their ability to trigger extracellular Aβ42 production by N2a-180
APP695 cells at 1, 10 and 100 µM (not shown). In parallel, cell viability assays were run to181
assess cell survival at these concentrations. The vast majority of products were unable to182
induce Aβ42 production. Among the few active products we identified several triazines. 183
Triazines are widely used as herbicides, anti-fouling agents or flame retardants (reviews in184
Lebaron et al. 2012). We next tested a library of 37 triazines representing the most produced185
triazines worldwide (1-37, Supplementary Table S1), along with Aftin-5 (38) as a positive186
control, on both N2a-APP695 and CHO-7PA2-APP751 cells for their ability to trigger Aβ42 187
production initially at 1, 10 and 100 µM (Supplementary Table S2). Six triazines were found188
to induce more than a 3-fold change in Aβ42 (Figure 1A, 1B): Ametryn, Prometryn, 189
Dipropetryn, Terbutryn, Cybutryne, Dimethametryn. As observed with Aftins (Bettayeb et al.190
2012; Hochard et al. 2013), Aβ42 production was strongly inhibited by inhibitors of β- 191
(inhibitor IV) and γ-secretases (BMS 299897, DAPT) and by a γ-secretase modulator (‘Torrey 192
Pines’ compound) (Figure 1C). Similarly, Aβ38 production was strongly reduced, while Aβ40 193
levels were only modestly affected (less than 2 fold increase) (not shown). Most of the194
triazines are metabolized in the environment. We thus tested some of the195
Cybutryne/Terbutryn metabolites (39-44) (Supplementary Figure S1) for their ability to196
trigger Aβ42 production in N2a-APP695 and CHO-7PA2 cells. None of the tested metabolites 197
was active as an inducer of Aβ42 production (not shown). We nest tested a library of 236 198
triazines that had been synthesized for affinity chromatography, for their ability to induce199
Aβ42 production (Ahn et al. 2007; Lee et al. 2009). Twenty-one of these (45-65) showed200
significant enhancement of Aβ42 production (Supplementary Table S3), showing that Aβ42 201
induction is an intrinsic property of some triazines. Affinity chromatography attempts with202
immobilized triazines did not allow us to purify specific targets, because of unselective203
hydrophobic interactions (not shown).204
Results were confirmed with HEK293-APPsw (not shown) and neurons derived from205
human iPSCs (see below). We also analyzed the effects of triazines on primary neuronal206
cultures prepared from E18 OFA rat embryo brains. Neurons were exposed to 100 µM of each207
triazine for 18 h, and the supernatants were collected for Aβ determination by ELISA assays. 208
Results show that triazines also induce an increase in Aβ42 production by primary neurons. 209
The Aβ-42/Aβ40 ratios were strongly increased (Figure 1D). 210
211
Mass spectrometry quantification and profile analysis of induced amyloids212
The amyloid peptides Aβ-38, Aβ40 and Aβ42 were quantified in the supernatants of 213
N2a-APP695 (Figure 2A) and CHO-7PA2-APP751 (Figure 2B) using SRM (Leinenbach et214
al. 2014; Pannee et al. 2013). Like Aftins (Bettayeb et al. 2012; Hochard et al. 2013), the215
triazines induced a reduction in Aβ38 levels, a slight increase or modest decrease in Aβ40 216
levels and a strong increase in Aβ42 levels (Figure 2, bottom). The Aβ42/Aβ40 ratios were 217
strongly increased (Figure 2, top).218
We next analyzed, by IP-MS, the range of Aβ produced by both cell lines exposed to 219
each of the six triazines and Aftin-5. Cell supernatants were collected, amyloid peptides were220
immunoprecipitated and analyzed using MALDI TOF/TOF (Brinkmalm et al. 2012; Portelius221
et al. 2013). Examples of spectra for N2a-APP695 and CHO-7PA2 cells exposed to222
Terbutryn, Aftin-5 and DMSO are provided in Figure 3A and 4A, respectively. Results show223
that exposure to triazines increased the production of Aβ 1-17, 11-42, 5-42 and 1-42, while 224
the production of Aβ 1-19, 1-27, 1-33, 1-38, 1-39 was reduced (Figure 3B, 4B). Other 225
amyloid peptides (including Aβ 1-40) showed only modest changes. Aβ 1-43, a highly 226
neurotoxic amyloid (Welander et al. 2009; Saito et al. 2011; Sandebring et al. 2013; Conicella227
et al. 2014) was undetectable in supernatants of control cells but strongly induced in Aftin-5228
and triazine-treated cells.229
230
Neurons differentiated from human iPSCs from AD patients and healthy controls.231
We next tested the effects of aftin-5 and the active triazines on neurons differentiated232
from human iPSCs derived from healthy individuals (APP WT, wild-type) or from AD233
patients (APP K724N mutation) (Mertens et al. 2013; Koch et al. 2012) (Figure 5). Neurons234
were first differentiated for either 4 or 10 weeks from iPSCs derived from healthy patient,235
before 24 h exposure to 100 µM Aftin-5 or Terbutryn (Figure 5A). Treatment resulted in a 2-3236
fold increase in the levels of Aβ42 levels compared to neurons exposed to DMSO. Aβ40 237
levels remained essentially unchanged. We next tested the effects of all six triazines on238
neurons differentiated from iPSCs (from healthy volunteer or AD patient with APP K724N)239
(Koch et al. 2009, 2012) (Figure 5B). APP K724N neurons produced more Aβ42 versus Aβ40 240
compared to APP WT neurons. Addition of Aftin-5 or any of the six active triazines resulted241
in a further increase in Aβ42 production, in both APP WT and APP K724N neurons. 242
243
APP sequence requirements for Aβ42 induction by triazines 244
To investigate the molecular mechanisms and possible epsilon cleavage sites245
requirement for the induced Aβ42 production, we generated six APP truncations and 246
expressed them in N2a cells (Figure 6A). All cell lines were the exposed first to 100 µM247
Aftin-5 and Aβ42 production was measured (Figure 6B). Full-length (FL) and the first three 248
truncations displayed enhanced Aβ42 production (Figure 6B). In contrast, the three last 249
truncations did not allow enhanced Aβ42 production when cells were exposed to Aftin-5. 250
Cells expressing FL APP and truncations 1, 3, 4 were next exposed to 100 µM of each251
triazine (Figure 6C). Aβ42 production assays show that although T3 allows stimulation of 252
Aβ42 production, T4 does not. These results reveal a strong APP structural requirement for 253
enhanced Aβ42 production induced by Aftin-5 and triazines, which seems to correspond to 254
the ε cleavage site of APP by y-secretase. At least 10 residues downstream of the Aβ42 255
cleavage site are required for the full effect of Aftin-5 and triazines.256
257
Triazines and Aftin-5 shift the cleavage pattern of the γ-secretase substrates alcadeins/ 258
calsyntenins259
Like APP, alcadeins/calsyntenins are sequentially cleaved by secretases, first by α-260
secretase, leading to an N-terminal and a C-terminal fragment, the latter being then cleaved by261
γ-secretase to an intracellular domain and the p3-Alcs peptide, in a way similar to APP (Hata 262
et al. 2009; Piao et al. 20013) (Figure 7A). To investigate the effects of triazines on alcadeins263
cleavage, we used HEK293 cells stably expressing full length alcadein α. Alcadein α is first 264
cleaved on the N-terminal side (two possible sites) followed by cleavage by γ-secretase 265
leading to p3-Alcα35 and p3-Alcα 2N+35, the later representing the major peptide in cultured 266
cells (Figure 7A). Cleavage at nearby sites (Figure 7A, blue arrows) leads to other peptides267
which are less abundant. HEK293-alcadein α cells were grown till 60% confluence and 268
treated with 100 µM Aftin-5 or triazines for 24 h. The secreted p3-Alcα peptides were 269
recovered and analyzed by MALDI TOF/MS (Figure 7B). Quantification of the different p3-270
Alc peptides showed that, compared to the p3-Alc peptide profile in vehicle treated cells, the271
concentration of the main alcadein peptide (p3-Alcα 2N+35) and the p3-37 peptide remained 272
stable. In contrast both p3-34 and p3-36 concentrations dropped by about 50 % and the p3-38273
peptide concentration increased massively (up to 28.1 fold for dimethametryn; 16.8 fold for274
Aftin-5) (Figure 7C). These results show that, like for APP, triazines and Aftin induce a shift275
in the cleavage pattern of alcadeins, another family of γ-secretase substrates, suggesting that 276
these products are more likely to interact with γ-secretase rather than its substrates. 277
278
279
DISCUSSION280
281
282
Induction of Aβ42 production, shift in Aβ42/Aβ40 ratio 283
Various drugs (fenofibrate, celecoxib, indomethacin, isoprenoids) (Kukar et al. 2005),284
DAPT under certain conditions (Svedružić et al. 2013; Barnwell et al. 2013), steroids (Jung et 285
al. 2013), ceramide analogs (Takasugi et al. 2015), SIN-1 (a peroxynitrite donor) (Guix et al.286
2012) have been shown to increase the Aβ42/Aβ40 ratio, mostly by increasing Aβ42 287
production, though never to the high level seen with Aftins (Bettayeb et al. 2012; Hochard et288
al. 2013). We anticipated that other chemical families able to trigger Aβ42 production would 289
be identified. We here show that some, but not all, widely used (though mostly banned290
nowadays) herbicide triazines induce the massive production of AD-associated Aβ42 in a 291
variety of cell types. Consequently the Aβ42/Aβ40 ratio is increased, as observed in both 292
EOAD (genetic origin) and LOAD (environmental, epigenetic origin). Detailed analysis of the293
produced amyloids reveals a pattern clearly associated with AD onset, such as increased Aβ1-294
16/17 (Portelius et al. 2011; Pérez-Grijalba et al. 2015), Aβ1/5/11-42, Aβ1-43 (Welander et 295
al. 2009; Saito et al. 2011; Sandebring et al. 2013; Conicella et al. 2014), and decreased Aβ1-296
33/37/38. The underlying molecular mechanisms remain unclear. However several remarks297
can be made:298
(1) there is a clear structure/activity relationship within triazines, as also observed with Aftins:299
not all products of the chemical class are active. This suggests specific molecular interactions300
rather than unspecific effects such as detergent, hydrophobic, membrane or protein structure301
disrupting actions.302
(2) the mechanism of action is more likely to involve an effect on γ-secretase and/or its micro-303
environment rather than an interaction with its substrates, as shown by the fact that Aftins and304
triazines also induce a shift in the cleavage pattern of alcadeins, another γ-secretase substrate. 305
The APP truncation experiments clearly suggest a very specific molecular requirement rather306
than a global, non-selective effect.307
(3) despite extensive proteomics studies (not shown) we were unable to detect308
major/significant modifications of protein expression that might be linked to the APP309
cleavage shift induced by triazines, suggesting that RNA or protein synthesis alterations are310
unlikely involved in the induction of Aβ42 production. We were also unable to identify a 311
specific target of triazines through affinity chromatography/proteomics approaches,312
suggesting that either the lipid raft comprising the γ-secretase or rather hydrophobic domains 313
of γ-secretase might constitute the real targets of triazines (and Aftins).  314
315
“Alzheimerogens” in the HCE?316
The virtual organic chemistry space accessible using currently known synthetic methods317
is estimated to be between 1020 and 1024 molecules (Ertl 2003). The Chemical Abstracts318
Service (CAS) registry, the World’s largest chemical database, contains more than 101319
million organic and non-organic substances. About 15,000 novel substances are registered320
every day, representing on average one new substance every 2.5 min. since 50 years321
(www.cas.org). Most of these compounds will never reach market and global exposure.322
However the US EPA Toxic Substances Control Act lists over 84,000 chemicals that are323
manufactured or imported at levels >10 tons per year, not including pesticides, cosmetics,324
food stuffs and food additives which are covered by other legislations (www.epa.gov). It is325
estimated that man is exposed to over 85,000 products. The REACH initiative assembles all326
products which are produced/imported at >100 tons/year (>1 ton/year by May 2018). All327
these products, along with all natural substances to which we are exposed from conception to328
death constitute the HCE (Wild 2005, 2012; Egeghy et al. 2012; Goldsmith et al. 2014).329
The impact of environment on health has been known since antiquity. Carcinogens330
have only been discovered in the last few decades. More recently the existence of endocrine331
disruptors and obesogens has been recognized. It is therefore no surprise that a small number332
of products may enter the human body, cross the blood brain barrier (BBB), alter specific333
molecular pathways in some of the human brain 1011 neurons and 1012 glia cells and thereby334
induce or contribute to specific CNS diseases. Identification of environmental factors335
involved in neurodegeneration and neurodegenerative diseases is in its infancy (reviews in336
Grandjean and Landrigan 2006, 2014; Cannon and Greenamyre 2011). The nervous system337
may be exposed to neurotoxic agents acutely (hours, days) or chronically (weeks, years,338
decades) before disease symptoms appear. Epidemiology studies are particularly difficult for339
neurodegenerative diseases since causes and effects are often separated by decades. These340
studies have therefore provided only few examples of environmental agents linked to the341
onset of neurodegenerative diseases. Pesticides, organic solvents, metals and some natural342
toxins (cyanobacteria) constitute the most frequently proposed neurotoxic agents. Two343
recently published books (Grandjean 2013; Demeneix 2014) review the impact of early age344
and even in utero exposure to environmental chemical entities on brain development and345
cognitive abilities.346
AD is one of the most prevalent and worrying CNS disease1. EOAD is clearly a347
genetic disease due to specific APP or PSEN1/2 mutations leading to overproduction of Aβ42 348
over Aβ40. However EOAD represents <1% of all AD cases. The origin of LOAD (sporadic 349
AD) (>99% of all AD cases) remains a mystery unsolved by epidemiological studies or by350
genome-wide association studies, which only revealed a few, low impact genetic risk factors351
(Lambert et al. 2013). The most prominent risk alleles, APOE ε4 and clusterin/ApoI link AD 352
to lipid metabolism. , and aging together with several environmental factors also impose an353
increased risk.. Exposure to numerous industrial and agricultural chemicals correlate with354
neurotoxicity (Grandjean an Landrigan 2006, 2014; Julvez et al. 2009; Cannon and355
Greenamyre 2011; Zeliger 2103). Elevated serum pesticides levels, in particular DDE, the356
major DDT metabolite, are associated with increased risk for AD (Richardson et al. 2014).357
DDT increases Aβ levels (Li et al. 2015). There are epidemiological links between exposure 358
to pesticides and AD (Hayden et al. 2010).359
1 According to the AD International Association the number of AD patients is expected to almost double in 20
years in the world, from 35.6 million in 2011 to 65.7 million in 2035. In Europe, the prevalence of AD is ~6.4%
over 65 years and ~20% over 80 years (EURODEM estimates). Women are three times more affected than men.
Life expectancy of patients at diagnosis is estimated at 3-8 years. AD is one of the most costly diseases for
developed economies. The global total estimated cost for dementia (of which AD is the most common form) is
604 billion $ in 2010 (70% in Western Europe and North America) (cost of illness EU27: 160 billion € (1.3% of
GDP) in 2008 of which 55% as informal care; 2.2 million life years lost due to disability; considerable weight
for patients caregivers; annual cost of 22 K€ per patient (2005), including 26% in medical expenses). (AD facts
& figures 2015).
Continuous sub-cutaneous injection of Aftin-5 in mice triggers robust dose-dependent360
increase in brain Aβ42 levels (unpublished data). Similar results were obtained with Aftin-4 361
(Meunier et al. 2014) and celecoxib or FT-1 (Kukar et al., 2005). Although orally362
administered triazines readily cross the BBB, their short half-life in mice prevented any363
accumulation, and consequently any effects on Aβ42 production in vivo (not shown).364
Based on results obtained with products belonging to various chemical classes, we365
propose the existence, in the HCE, of products able to increase the production of the AD-366
associated Aβ42 and Aβ43 peptides. Such products might be classified as potential 367
“Alzheimerogens” if long exposure, slow turn-over, low elimination and high BBB368
permeability allow long-term accumulation in the brain and action on brain cells. It is difficult369
to predict whether very long term, daily exposures of humans to the triazines described here370
might have resulted in sustained increase in Aβ42 production. We are now investigating other 371
Aβ42 inducers which have a long half-life both in the environment and in the body, which 372
accumulate in adipose tissues and which cross the BBB. We believe that such products may373
contribute to the onset, development and acceleration of sporadic LOAD. It is intriguing that374
both Aftin and triazines were able to stimulate Aβ42 production in human cells displaying a 375
pathological APP mutation and already showing enhanced Aβ42 production. This suggests 376
that environmental factors may synergize with genetic/epigenetic factors in enhancing Aβ42 377
production and triggering AD. Identification of such potential “Alzheimerogens” in the HCE378
and regulation of human exposure to them should open the way to innovative AD prevention379
strategies.380
381
CONCLUSIONS382
Like Aftins, and a few other chemicals of various structures, some widely used383
triazines trigger massive production of AD-associated Aβ42. These results suggest that HCE 384
may contain other products to which humans are exposed on a long-term basis and which may385
contribute to the initiation, development or acceleration of AD. Identification and regulation386
of such potential “Alzheimerogens” should be a priority for the implementation of effective387
strategies to prevent the very common sporadic AD. In addition, some of these products might388
be turned into pharmacological tools to develop a chemically-induced animal model of AD,389
with fundamental and applied potential similar to the MPTP -induced Parkinsonism model390
(Fox and Brotchie 2010).391
392
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FIGURE LEGENDS558
559
Figure 1. Some triazines trigger β- and γ-secretase dependent production of 560
extracellular Aβ42. A. Effect of 37 triazines on extracellular Aβ42 production by N2a-561
APP695 and CHO-7PA2-APPsw cells. Cells were treated with 100 µM of each compound for562
18 h and cell supernatants were collected for Aβ42 levels measurement by ELISA. Aftin-5 563
was used as a positive control and the corresponding volume of vehicle (DMSO) as a negative564
control. Levels are expressed as fold change, + SE, of Aβ42 levels over those of control, 565
vehicle-treated cells. Average of two experiments performed in triplicate (representative of566
four independent experiments). Horizontal dotted lines indicate levels for 1 and 3 fold567
changes in Aβ42 concentration. B. Structure of the six active triazines and of Aftin-5. C.568
Extracellular Aβ42 production induced by triazines is inhibited by β-secretase inhibitor IV, γ-569
secretase inhibitors DAPT & BMS 299897 and γ-secretase modulator 'Torrey Pines' 570
compound. N2a-APP695 cells were exposed to 10 µM of each inhibitor. 1.5 h later cells were571
exposed to 100 µM of each active triazine or 50 µM Aftin-5. Extracellular Aβ42 levels were 572
measured after 18 h. Representative of two independent experiments performed in triplicates.573
D. Triazines trigger Aβ42 production in primary rat neuron cultures. Cells were exposed to 574
DMSO, 100 µM of each triazine or Aftin-5 for 18 h. Cell supernatants were collected and the575
levels of Aβ38, Aβ40 and Aβ42 (bottom panel) were determined by ELISA assays (average 576
of triplicate values). The Aβ-42/Aβ40 ratios were calculated (top panel). The horizontal 577
dotted line refers to the basal ratio in control cells.578
579
Figure 2. Mass spectrometry quantification of Aβ38, Aβ40 and Aβ42. Levels of the three580
amyloid peptides were determined by mass spectrometry in supernatants of N2a-APP695 (A)581
and CHO-7PA2-APPsw (B) cells following 18 h treatment with DMSO, 100 µM of each582
triazine or Aftin-5. Amyloid levels are expressed as percentage of levels in vehicle-treated583
cells (bottom panels; average + SE of triplicate values; absolute values in control cell584
supernatants are indicated under the bottom panels) and Aβ42/Aβ40 ratios (top panels; 585
horizontal dotted lines refer to the basal ratios in control cells).586
587
Figure 3. Pattern of amyloid peptides produced by N2a-APP695 cells exposed to588
triazines. Cells were treated for 18 h with DMSO, 100 µM of each triazine or Aftin-5. Cell589
supernatants were collected and analyzed as described. A. Example spectra of supernatants590
amyloid profiles from N2a-APP695 cells exposed to DMSO, Aftin-5 or Terbutryn. B.591
Quantification of all amyloid peptides in N2a-APP695 cell supernatants (Log of fold change592
in triazine or Aftin-5 treated cells over control, DMSO-treated cells).593
594
Figure 4. Pattern of amyloids peptides produced by CHO-7PA2-APPsw cells exposed to595
triazines. Cells were treated for 18 h with vehicle, 100 µM of each triazine or Aftin-5. Cell596
supernatants were collected and analyzed as described. A. Example spectra of supernatants597
amyloid profiles from CHO-7PA2-APPsw cells exposed to DMSO, Aftin-5 or Terbutryn. B.598
Quantification of all amyloid peptides in CHO-7PA2-APPsw cell supernatants (Log of fold599
change in triazine or Aftin-5 treated cells over control, DMSO-treated cells).600
601
Figure 5. Triazines trigger enhanced production of Aβ42 versus Aβ40 in neurons 602
differentiated from human iPSCs. A. iPSCs-derived neurons were differentiated for 4 or 10603
weeks and then exposed to DMSO or 100 µM Aftin-5 or Terbutryn for 24 h. B. Neurons were604
derived from iPSCs obtained from healthy donor (APP WT) or from an AD patient (APP605
K724N mutation). They were exposed for 24 h to DMSO, 100 µM Aftin-5 or the six triazines.606
In both experiments cell supernatants were collected for extracellular Aβ levels measurement 607
by ELISA. Levels are expressed as Aβ42/Aβ40 ratios + SE of triplicate values.  608
609
Figure 6. Effect of APP C-terminal truncations on triazines’ efficacy. A. Only the C-610
terminal aa sequences of APP full length (WT) and C-terminal truncations mutants (T1-T6)611
are shown. The γ and ε cleavage sites are indicated in orange and blue respectively. Numbers 612
indicate the position of the residues involved in those cleavages and refer to the α cleavage 613
site. B. Mutants T1 to T6 were expressed transiently in N2a cells which were exposed to614
DMSO or Aftin-5 (100 µM) for 24 hrs and the levels of released Aβ42 was measured by 615
ELISA. C. Mutants T1, T3 and T4 expressing N2a cells were exposed for 24 hrs to DMSO616
(D), Aftin-5 or the six triazines (100 µM). Aβ42 level were measured and are expressed as 617
fold-increase vs. untreated cells.618
619
Figure 7. Triazines alter the cleavage pattern of alcadein α, leading to increased p3-620
Alcα38 production. A. Schematic representation of the production of p3-Alcα peptides from 621
Alcadein α. The full length protein is cleaved primarily by α-secretase at His814 or Ala816 622
(purple arrows). It is then cleaved by γ-secretase at Thr851 (orange arrow) leading to the two 623
main Alcadein α peptides p3-Alcα35 and p3-Alcα2N+35 (‘2N’ denotes the two additional, N-624
terminal amino acids). Alternative cleavage sites (blue arrows) generate additional p3-Alcα 625
peptides of different sizes. B. Immunoprecipitation/mass spectrometry resolution of p3-Alcα 626
peptides produced by HEK-Alcadein α cells exposed to various triazines, Aftin-5 or DMSO. 627
Cells were treated for 24 h with 100 µM of each reagent and p3-Alc peptides were analyzed628
by MALDI-TOF/MS. Representative profiles for each product (top) and zoom on the p3-629
Alcα34, p3-Alcα35 and p3-Alcα38 peaks (bottom). C. Quantification of p3-Alcα peptides 630
produced by cells exposed to all triazines and Aftin-5. Levels of each peptide are presented as631
fold change of ratios over p3-Alcα35 versus corresponding peptide ratios for DMSO-treated 632
cells. Horizontal dotted lines indicate levels for 1 fold change in p3-Alcα/p3-Alcα35 ratio in 633
treated vs. control cell supernatant. Note the change of scale for p3-Alcα38/p3-Alcα35 634
treated/control ratio.635
